Physician profile
Timothy Collins
NPI 1235126392
$8,816.27
in general payments reported to CMS, 2019-2025
33 companies · $1,188 in 2025
The $1,188 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $1,432 · 2021: $1,521 · 2022: $1,518 · 2023: $1,191 · 2024: $918 · 2025: $1,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,291 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,290.54 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,505.25 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $1,379.36 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,014.37 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $604.81 | 2019-2024 | Jardiance |
| Abbvie INC. | $586.22 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $556.71 | 2022-2025 | |
| Pfizer INC. | $512.19 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $285.02 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $269.42 | 2019-2022 | |
| Amgen INC. | $262.51 | 2020-2023 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $236.10 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $225.62 | 2020-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $221.07 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $198.13 | 2024-2025 | Caplyta |
| Abbott Laboratories | $124.12 | 2022-2025 | Freestyle Libre 3 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $103.91 | 2022-2024 | Seglentis, Zoryve |
| Glaxosmithkline, LLC. | $97.00 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $94.50 | 2021-2025 | Gvoke Hypopen |
| Medtronic, INC. | $89.53 | 2025 | Minimed 780g |
| Exact Sciences Corporation | $57.96 | 2023-2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $57.74 | 2025 | Auvelity |
| Eisai INC. | $46.02 | 2020 | |
| Paratek Pharmaceuticals, INC. | $42.03 | 2023 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $40.51 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.51 | 2022 | |
| Allergan, INC. | $30.16 | 2020 | |
| Esperion Therapeutics, INC. | $28.72 | 2021 | |
| Phathom Pharmaceuticals, INC. | $20.39 | 2024 | Voquezna |
| Astellas Pharma US INC | $20.33 | 2024 | Veozah |
| Scilex Pharmaceuticals INC. | $19.79 | 2025 | |
| Dexcom, INC. | $19.75 | 2021 | |
| Evoke Pharma, INC. | $17.66 | 2025 | |
| Sunovion Pharmaceuticals INC. | $16.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.